Synonym
SW044248; SW-044248; SW 044248.
IUPAC/Chemical Name
2-((5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(2-methoxyphenyl)butanamide
InChi Key
PEVRGVRHMMZNGI-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H23N5O2S/c1-4-18(21(28)23-15-11-7-9-13-17(15)29-3)30-22-24-20-19(25-26-22)14-10-6-8-12-16(14)27(20)5-2/h6-13,18H,4-5H2,1-3H3,(H,23,28)
SMILES Code
CCN1C2=CC=CC=C2C3=C1N=C(N=N3)SC(C(NC4=CC=CC=C4OC)=O)CC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
SW044248 is a topoisomerase I inhibitor.
In vitro activity:
To investigate the mechanism of action of SW044248, the effect of the compound on DNA replication, global RNA synthesis and protein synthesis was determined. HCC4017 and HBEC30KT cells were treated with increasing concentrations of SW044248 for 5 hours followed by labeling for an additional 45 minutes with alkyne-modified nucleotide analogs, 5-ethynyl-2’-deoxyuridine (EdU) for studying DNA replication, 5-ethynyl-2’-uridine (EU) for RNA transcription or amino acid homopropargylglycine (HPG) for studying protein translation. SW044248 rapidly blocked DNA replication, transcription of RNA and protein translation in HCC4017 cells (Figure 2A) and H292 cells (Figure S2A) but not in resistant HBEC30KT cells (Figure 2B) or HCC44 cells (Figure S2A).
Reference: Mol Cancer Ther. 2016 Jan;15(1):23-36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707128/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
10.5 |
24.91 |
| DMF |
5.0 |
11.86 |
| Ethanol |
1.0 |
2.37 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
421.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Zubovych IO, Sethi A, Kulkarni A, Tagal V, Roth MG. A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines. Mol Cancer Ther. 2016 Jan;15(1):23-36. doi: 10.1158/1535-7163.MCT-15-0458. Epub 2015 Dec 14. PMID: 26668189; PMCID: PMC4707128.
In vitro protocol:
1. Zubovych IO, Sethi A, Kulkarni A, Tagal V, Roth MG. A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines. Mol Cancer Ther. 2016 Jan;15(1):23-36. doi: 10.1158/1535-7163.MCT-15-0458. Epub 2015 Dec 14. PMID: 26668189; PMCID: PMC4707128.
1: Zubovych IO, Sethi A, Kulkarni A, Tagal V, Roth MG. A Novel Inhibitor of
Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer
Cell Lines. Mol Cancer Ther. 2016 Jan;15(1):23-36. doi:
10.1158/1535-7163.MCT-15-0458. Epub 2015 Dec 14. PubMed PMID: 26668189; PubMed
Central PMCID: PMC4707128.
2: Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J,
Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei
S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis
RJ, Roth MG, Minna JD, White MA. Systematic identification of molecular
subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013 Oct
24;155(3):552-66. doi: 10.1016/j.cell.2013.09.041. Epub 2013 Oct 24. PubMed PMID:
24243015; PubMed Central PMCID: PMC3836195.
